Therefore, HLA‐DRB1 and SYK have been identified as potential pharmacological targets for modulating the risk of MS, with HLA‐DRB1, in particular, being highlighted as a key target based on findings from both SMR and colocalisation analyses. Here, SYK is linked to myeloid sarcoma.